About Us

Stephen Van Deventer

Chief Executive Officer & President

Stephen is the Chairman and CEO of BioGene Therapeutics and PreveCeutical Medical, with over 30 years of experience in capital markets with a focus on life sciences. Stephen has started and raised millions in the capital markets space and launched companies into the public markets in Canada, the United States and Europe.

Alex McAuly, CPA

Chief Financial Officer

Serves as the CFO for BioGene. Alex is a Chartered Professional Accountant of Canada with vast experience in running publicly traded companies through his astute knowledge of accounting principles in North America and Europe.

Harry Parekh, PhD

Chief Science Officer

Harry is welcomed to the BioGene team as Chief Research Officer & Scientific Founder of BioGene. Harry is currently a Director of Research and Research Group Leader at the University of Queensland, Australia. He also serves as CRO & Scientific Founder for PreveCeutical Medical.

Dr. Parekh heads the Drug/Gene Delivery Group at PACE-UQ with his team developing highly innovative and translational medicine delivery systems in-conjunction with physicians whose expertise span cancer, obesity-&-diabetes, macular disease, infectious disease and traditional (Chinese) medicine.

Francis Tavares, PhD

Chief Technology Officer

Francis serves as Chief Technology Officer of BioGene Therapeutics. He has extensive experience in the preclinical development of small inhibitors in various target classes. He is founder of and CEO of ChemoGenics BioPharma and has successfully supported multiple programs, including some that have attracted Venture Capitalist investment to further develop their assets for commercialization.

Kamal Albarazanji

Senior Director of Metabolic Research

Kamal joins BioGene Therapeutics as the Senior Director of Metabolic Research. He is a prolific researcher with a wealth of experience in in vivo pharmacology, target validation, and translational research with numerous patents and peer-reviewed manuscripts. His career spans notable roles at SmithKline Beecham (now GSK), where he contributed to groundbreaking work on renin inhibitors for hypertension, insulin sensitizers like Avandia, and neuropeptide programs for obesity.

Kimberly Van Deventer

Executive Assistant

Ms. Van Deventer is an entrepreneur with a successful track record of accomplishment that she brings to Biogene. Motivated and determined, she was ranked the third highest-grossing female business owner in BC, Canada in 2009 and a founding member of Preveceutical Medical Inc.. Kim is a driving force behind the business and is unwavering in her commitment to bring awareness of health and disease prevention to people everywhere.

Sydney Cole

Administration Manager

Sydney Cole is a founding member of Biogene Therapeutics and PreveCeutical Medical Inc.. With a decade of experience in corporate administration, bookkeeping and capital raises Ms. Cole’s organization and fortitude keep operations running smoothly.